OBJECTIVE: To determine the frequency, the clinical and laboratory associations, and the impact on survival of anti-dsDNA, anti-Sm, anti-nRNP, anti-Ro, and anti-La in patients with systemic lupus erythematosus (SLE). METHODS: The clinical and laboratory features of 94 patients with SLE tested for anti-dsDNA, anti-nRNP, anti-Sm, anti-Ro and anti-La were studied. Survival analyses were performed by the Kaplan Meier method. RESULTS: Anti-Ro, anti-nRNP and anti-Sm were found with lower frequency in our patients compared to other reports. There was a higher frequency of anti-Sm (19.5 vs 10%, p = 0.0093) and anti-nRNP positivity (29.2 vs 7.5%, p = 0.006) among African American patients compared to Caucasian patients. No clinical or laboratory associations were found with any of the autoantibodies. Patients had a mean followup up 11.8 years. There were no protective or negative effects of the different autoantibodies on the probability of survival of the patients studied. CONCLUSION: Our study failed to demonstrate the impact of the autoantibodies studied in the survival of our patients.
OBJECTIVE: To determine the frequency, the clinical and laboratory associations, and the impact on survival of anti-dsDNA, anti-Sm, anti-nRNP, anti-Ro, and anti-La in patients with systemic lupus erythematosus (SLE). METHODS: The clinical and laboratory features of 94 patients with SLE tested for anti-dsDNA, anti-nRNP, anti-Sm, anti-Ro and anti-La were studied. Survival analyses were performed by the Kaplan Meier method. RESULTS: Anti-Ro, anti-nRNP and anti-Sm were found with lower frequency in our patients compared to other reports. There was a higher frequency of anti-Sm (19.5 vs 10%, p = 0.0093) and anti-nRNP positivity (29.2 vs 7.5%, p = 0.006) among African American patients compared to Caucasian patients. No clinical or laboratory associations were found with any of the autoantibodies. Patients had a mean followup up 11.8 years. There were no protective or negative effects of the different autoantibodies on the probability of survival of the patients studied. CONCLUSION: Our study failed to demonstrate the impact of the autoantibodies studied in the survival of our patients.
Authors: Mariangelí Arroyo-Ávila; Yesenia Santiago-Casas; Gerald McGwin; Ryan S Cantor; Michelle Petri; Rosalind Ramsey-Goldman; John D Reveille; Robert P Kimberly; Graciela S Alarcón; Luis M Vilá; Elizabeth E Brown Journal: Clin Rheumatol Date: 2015-04-22 Impact factor: 2.980
Authors: Ekemini A Ogbu; Shanmuganathan Chandrakasan; Kelly Rouster-Stevens; Larry A Greenbaum; Ignacio Sanz; Scott E Gillespie; Chelsea Marion; Karli Okeson; Sampath Prahalad Journal: Lupus Date: 2020-10-27 Impact factor: 2.911
Authors: Sara Croca; Paul Bassett; Charis Pericleous; Karim Fouad Alber; David Latchman; David Isenberg; Ian Giles; Anisur Rahman; Yiannis Ioannou Journal: Arthritis Res Ther Date: 2014-02-07 Impact factor: 5.156
Authors: María Elena Soto; Nidia Hernández-Becerril; Ada Claudia Perez-Chiney; Alfredo Hernández-Rizo; José Eduardo Telich-Tarriba; Luis Eduardo Juárez-Orozco; Gabriela Melendez; Rafael Bojalil Journal: Results Immunol Date: 2013-11-09
Authors: Sahwa Elbagir; Amir I Elshafie; Elnour M Elagib; NasrEldeen A Mohammed; Mawahib I E Aledrissy; Azita Sohrabian; Musa A M Nur; Elisabet Svenungsson; Iva Gunnarsson; Johan Rönnelid Journal: Rheumatology (Oxford) Date: 2020-05-01 Impact factor: 7.580